Swedish Cancer Institute opens Robert and Jean Reid Family Innovative Therapeutics & Research Unit

March 22, 2016
Swedish announced today, as part of the Swedish Cancer Institute (SCI), the opening of a new clinical trial center named the Robert and Jean Reid Family Innovative Therapeutics & Research Unit (ITU). This state-of-the-art clinical project will be an early-phase clinical trials unit focused on investigational therapies that are driven by our SCI Personalized Medicine Program, specifically by biologically targeted therapies. This includes therapies directed by genomics, transcriptomics, proteomics, metabolomics, micro-biomics, and immunological profiling.

“This is a tremendous resource for our community and was made possible by the Reid family and other generous donors,” said Thomas D. Brown, MD, MBA, Executive Director, Swedish Cancer Institute. “I am grateful for the very large team of caregivers that worked diligently to make this important project a reality.”

The unit will not only expand clinical trials and research programs at Swedish for cancer, it will also double the number of early phase I clinical trials. Cancer patients will now have access to more new agents, ground-breaking cancer treatments and technologies.

The Reid Family ITU is designed to be patient and family centered, while including the highest level of space planning and technology to support the administration of novel therapies, and the associated high level monitoring for patients receiving such.

The Reid Family ITU includes: supportive care and nourishment space for patients and families; 16 treatment chairs; five private rooms, to include one with positive and negative ambient pressure capabilities; a specimen preparation and handling laboratory to facilitate pharmaco-kinetic and pharmaco-dynamic analyses; data management space; a conference room with tele-conferencing capability; and an investigational and general oncologic pharmacy.

Initially some patients with routine infusions will be cared for on this unit, but over time, the unit will be entirely dedicated to administration of investigational therapies, especially phase I and II therapeutics.

For more information about the Swedish Cancer Institute, visit www.swedish.org/cancer.